# US 8,784,816 B2 · Antibodies which bind factor VIII

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,784,816 B2
- Document ID: US8784816B2
- Status: Granted
- Kind: B2
- Application number: 13/658,365
- Filed: 2012-10-23
- Published: 2013-05-30
- Granted: 2014-07-22
- Earliest claimed: 1999-07-14
- Assignees: Life Sciences Research Partners VZW
- Applicants: Marc G. Jacquemin; Jean-Marie R. Saint-Remy
- Inventors: Marc G. Jacquemin; Jean-Marie R. Saint-Remy
- Web page: https://patentgrep.com/patent/US8784816B2

## CPC

- C07K 16/36: against blood coagulation factors
- A61K 39/39533: {against materials from animals}
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention, in general, features a method of treatment and/or prevention of a thrombotic pathological condition, in a mammal, which includes administering to the mammal in need of such treatment a therapeutically effective amount of a composition including an antibody directed against the C1 domain of Factor VIII, which is a partially inhibitory antibody of Factor VIII.

## Claims

### Claim 1

An isolated monoclonal antibody directed against factor VIII which is partially inhibiting factor VIII procoagulant activity, wherein said antibody is comprising:
heavy chain variable region CDR1, CDR2 and CDR3 corresponding to SEQ ID NOs: 33, 34 and 35, respectively, and light chain variable region CDR1, CDR2 and CDR3 corresponding to SEQ ID NOs: 36, 37 and 38, respectively; or
heavy chain variable region CDR1, CDR2 and CDR3 corresponding to SEQ ID NOs: 39, 40 and 41, respectively, and light chain variable region CDR1, CDR2 and CDR3 corresponding to SEQ ID NOs: 42, 43 and 44, respectively;
or an antigen-binding fragment of any of said antibodies.

### Claim 2 (depends on 1)

A pharmaceutical composition comprising the monoclonal antibody of claim 1 in admixture with a pharmaceutically acceptable carrier.

### Claim 3 (depends on 1)

A method of treatment of a thrombotic pathological condition involving factor VIII in a mammal, wherein, in said condition, the risk of clot formation is increased, said method comprising administering to said mammal in need of such treatment an effective amount of a composition comprising the antibody according to claim 1.